Fes. Recell is a good product for its intended use and to ours. Purchase of Recell for us is not a priority and I think cross promotion of both products by PNV and AVH makes sense as they are complementary and not competing IMO. I don’t believe that we would get any higher market share by offering both as one product or solution. I think DW and AVH management came to the conclusion that “I scratch your back you scratch mine” Is not a bad way to promote 2 good products that complement each other at present.
The Clinicians Speak, page-1021
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
0.110(4.74%) |
Mkt cap ! $1.677B | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.45 | $2.38 | $2.896M | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 9997 | 4 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |